Homologous Recombination Deficiency Pathway (HRD)

Homologous recombination deficiency describes failure or impairment within the high-fidelity homologous recombination DNA repair system. It results from genetic or epigenetic changes affecting core components like *BRCA* genes. Clinically relevant both diagnostically and therapeutically—especially regarding targeted therapies like PARP inhibitors—HRD status guides treatment decisions across multiple solid tumor types by identifying patients most likely to benefit from specific interventions targeting defective DNA damage response pathways.

Synthetic lethality in HRD tumors with PARP inhibitors; Induction of double-strand breaks with platinum-based chemotherapies